From NAFLD to MASLD: Promise and pitfalls of a new definition

Affiliations

¹ Division of Endocrinology, Diabetes and Metabolism the University of Florida, Gainesville, FL, USA. Electronic address: Kenneth.cusi@medicine.ufl.edu.
² Global NASH Council Center for Outcomes Research in Liver Diseases, Washington, DC, USA. Electronic address: zobair.younossi@cldq.org.
³ Department of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich Heine University, Düsseldorf, Germany; Institute for Clinical Diabetology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany. Electronic address: michael.roden@ddz.de.

Kenneth Cusi et al. J Hepatol. 2024 Jul.

. 2024 Jul;81(1):e18-e19.

doi: 10.1016/j.jhep.2023.09.038. Epub 2023 Dec 19.

¹ Division of Endocrinology, Diabetes and Metabolism the University of Florida, Gainesville, FL, USA. Electronic address: Kenneth.cusi@medicine.ufl.edu.
² Global NASH Council Center for Outcomes Research in Liver Diseases, Washington, DC, USA. Electronic address: zobair.younossi@cldq.org.
³ Department of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich Heine University, Düsseldorf, Germany; Institute for Clinical Diabetology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany. Electronic address: michael.roden@ddz.de.

No abstract available

Comment in

Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.
Rinella ME, Castro Narro GE, Krag A, Terrault N, Newsome PN. Rinella ME, et al. J Hepatol. 2024 Jul;81(1):e20-e21. doi: 10.1016/j.jhep.2023.10.008. Epub 2023 Dec 19. J Hepatol. 2024. PMID: 38906627 No abstract available.